SynthesisBMC cancer2025

Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis.

Fanqiao Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.